GILD: Gilead Sciences, Inc. - Summary | Jitta

Gilead Sciences, Inc.

NASDAQ:GILD

End of day
Dec 14, 2018
Price
$65.57
Loss Chance
46.0%
3.80
Updated 2018Q3
last month
Nov 09, 2018
JITTA SCORE
24.83%Above Jitta Line
Jitta Ranking
188 / 795
United States
?
NASDAQ, NYSE
2,411 / 4,758
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (5)
Recent Business Performance (15)
Financial Strength (70)
Return to Shareholders (95)
Competitive Advantage (84)
Jitta Signs
Debt Level
20132014201520162017
Net Profit (mill.)3,075.0012,101.0018,108.0013,841.814,853.63
Long Term Debt (mill.)3,939.0011,921.0021,073.0026,346.0030,795.00
Low Long Term Debt
Return on Equity
20132014201520162017
ROE (%)26.8978.3797.6973.2923.74
Consistently High
Share Repurchase
20132014201520162017
Common Shares (mill.)1,534.001,499.001,422.001,310.001,308.00
Every Year
CapEx
20132014201520162017
CapEx per Share0.120.370.530.570.45
Earning per Share2.008.0712.7310.573.71
Very Low
Revenue and Earning
201220132014201520162017
Revenue6.397.3016.6022.9523.2019.96
EPS1.862.008.0712.7310.573.71
Earning decline from 2014-2017
Recent Business Performance
Earning per ShareQ1Q2Q3Q4
20181.161.451.52-
20172.072.352.08-2.79
20162.712.632.592.49
Earning decline 64.94% in the last year
Key Stats
Jitta Score
Jitta Line
3.80
24.83%
1.82
0.85%
2.44
0.48%
Biotechnology
COMPANY DESCRIPTION
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.